CrystalGenomics Presents Poster on Combination Therapy Study of Ivaltinostat for Arthritis

CrystalGenomics announced on the 17th that it presented research results on a new method of arthritis treatment combining 'Ivaltinostat' and 'Polmacoxib' (brand name Aselex) in a poster session at the Spring Conference of the Korean Society for Immunology held on the 14th at the Gwangju Institute of Science and Technology (GIST).

Presentation poster set up at the site of the Korean Society for Immunology Spring Conference held on the 14th [Photo by Crystal Genomics]

The presentation included research findings that co-administration of Ivaltinostat and Polmacoxib in a collagen-induced arthritis mouse model significantly reduced arthritis symptoms, inflammatory cytokines, bone erosion, and cartilage destruction. Additionally, the research team revealed that the combined administration of the two drugs in rat synovial cells and RAW 264.7 cells decreased the invasiveness of synovial cells and markedly inhibited the production of osteoclasts induced by a protein called RANKL. Osteoclasts are cells that break down bone tissue and cause bone erosion and cartilage destruction in arthritis.

Dr. Youngdae Kim, the lead researcher at CrystalGenomics, explained that the study results demonstrated that "the co-administration of Polmacoxib and Ivaltinostat is superior to existing drugs such as tofacitinib (a Janus kinase (JAK) inhibitor), improves joint inflammation caused by chronic inflammation, and shows promise as a new therapeutic strategy for rheumatoid arthritis (RA) that alleviates permanent joint damage."

Meanwhile, Ivaltinostat is a histone deacetylase (HDAC) inhibitor that suppresses cell proliferation and invasion, and Polmacoxib is a cyclooxygenase (COX)-2 inhibitor that reduces inflammation. Polmacoxib has been sold domestically as a treatment for osteoarthritis since 2017, and Ivaltinostat is currently undergoing a Phase 1b clinical trial in the United States.

This content was produced with the assistance of AI translation services.